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Background: The enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) converts inactive cortisone into
active cortisol in insulin target tissues. In people with type 2 diabetes, skeletal muscle (SkM) 11βHSD1 is
upregulated by the potent glucocorticoid dexamethasone. The HSD11B1 gene has two promoters designated P1
and P2. CCAAT/enhancer-binding protein beta (C/EBPβ) is known to regulate expression of 11βHSD1 via the P2
promoter. In this study, we investigated the potential role of altered DNA methylation of the P1 and P2 promoters
in the observed dexamethasone-induced upregulation of SkM 11βHSD1 oxoreductase activity in human diabetic
subjects. SkM biopsies from 15 people with type 2 diabetes were collected before and after treatment with oral
dexamethasone 4 mg/day for 4 days and SkM 11βHSD1, C/EBPβ and P1 and P2 promoter region mRNA levels were
measured by quantitative RT-PCR. 11βHSD1 oxoreductase activity was quantified by measuring the conversion of
radiolabeled 3H-cortisone to cortisol by thin layer chromatography. Analysis of HSD11B1 promoter methylation
(P1 and P2) was performed using Sequenom MassARRAY EpiTYPER analysis.
Results: Dexamethasone treatment resulted in a significant increase in 11βHSD1 mRNA levels (P = 0.003),
oxoreductase activity (P = 0.017) and C/EBPβ mRNA (P = 0.015), and increased expression of both the P1 (P = 0.008)
and P2 (P = 0.016) promoter regions . The distal P1 promoter region showed a significant reduction in methylation
following dexamethasone (P = 0.026). There was a significant negative correlation between the change in
methylation at this site and the increment in 11βHSD1 oxoreductase activity (r = −0.62, P = 0.014).
Conclusions: Our findings of reduced methylation in the HSD11B1 P1 promoter in association with increased
11βHSD1 oxoreductase activity implicate complex multi-promoter epigenetic mechanisms in the regulation of
11βHSD1 levels in SkM.
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11β-Hydroxysteroid dehydrogenase-1 (11βHSD1) is a
bi-directional enzyme, most abundantly expressed in
glucocorticoid target tissues such as the liver and adi-
pose [1]. 11βHSD1 displays predominant oxoreductase
activity in intact cells, generating the biologically active* Correspondence: warrick_inder@health.qld.gov.au
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reproduction in any medium, provided the orglucocorticoid cortisol from the inactive form, corti-
sone [2]. In adipose tissue, several studies show
increased 11βHSD1 expression and oxoreductase ac-
tivity, suggesting that differential elevation of gluco-
corticoid in this tissue may be involved in the
pathogenesis of central obesity [3]. Skeletal muscle
(SkM) is a major site of insulin resistance and
accounts for the majority of peripheral glucose dis-
posal [4]. We have previously demonstrated that
11βHSD1 is present and biologically active in SkM of
both diabetic and nondiabetic subjects [5].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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demonstrated that addition of glucocorticoid upregulates
11βHSD1 mRNA levels and activity [6]. This is consist-
ent with other studies in a variety of human tissues in-
cluding skin fibroblasts [7], amnion fibroblasts [8], and
omental adipose stromal cells [9] that implicate
glucocorticoids in 11βHSD1 upregulation. Our own data
in people with type 2 diabetes showed that orally
administered dexamethasone increases SkM 11βHSD1
oxoreductase activity [5], but this response was not
observed in nondiabetic subjects.
Dexamethasone increases 11βHSD1 mRNA levels and
activity in cultured chorionic trophoblasts, an effect that
is blocked by the glucocorticoid receptor antagonist
RU486 [10]. Co-localization of 11βHSD1 and the gluco-
corticoid receptor was demonstrated [10]. This indicates
that the stimulatory effect of glucocorticoids on
11βHSD1 is likely to be mediated via the glucocorticoid
receptor. Glucocorticoids appear to act in an autocrine
manner, stimulating the expression of 11βHSD1, which
in turn increases conversion of cortisone to active corti-
sol, a so-called positive feed-forward mechanism [11].
The human genome contains two annotated transcrip-
tion start sites for the HSD11B1 gene (encoding
11βHSD1), which are potentially regulated in an inde-
pendent manner in different tissues (Figure 1). However,








Figure 1 Location of the HSD11B1 promoter methylation assays used in
individual CpG dinucleotides (dashes) and methylation assay location (black bo
(vertical blue dashes, exons; arrowed lines, introns – according to the UCSC ge
P1 and P2 refer to two independent promoters examined in this study. (B) Hig
adjacent to a conserved putative glucocorticoid response element (GRE)) and a
measurement of methylation levels by Sequenom). (C) Sequence of conserved
the CpG site assayed in this study (red lettering).poorly understood. Several studies have demonstrated
the importance of the CCAAT/enhancer-binding protein
(C/EBP) transcription factors [11-16] in HSD11B1 ex-
pression from the proximal P2 promoter. In human
A549 lung epithelial cells, C/EBPβ has been shown to
mediate the induction of 11βHSD1 by glucocorticoids
[13], whereas in human amnion fibroblasts C/EBPα ra-
ther than C/EBPβ was involved [11]. However, inhibition
of C/EBP is insufficient to completely block glucocortic-
oid stimulation of 11βHSD1 activity, at least in some
cells [11].
DNA methylation is an epigenetic process that plays a
pivotal role in the regulation of gene expression in both
a temporal and spatial manner throughout development
[17]. Methylation of DNA in vertebrates occurs almost
exclusively in CpG dinucleotides, often clustered in gene
promoter regions. Promoter methylation is generally
associated with reduced gene activity. Changes in pro-
moter methylation may occur in a dynamic fashion with
measured periodicity of as little as 100 minutes [18,19].
The observed induced 11βHSD1 enzyme activity
following glucocorticoid treatment may therefore poten-
tially be associated with a reduction in HSD11B1 pro-
moter methylation. Each of the two annotated HSD11B1
promoters contains CpG sites, one of which (within the
distal P1 promoter) overlaps a conserved glucocorticoid
response element (GRE; Figure 1).P2
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http://www.clinicalepigeneticsjournal.com/content/4/1/24In this study, we tested the hypothesis that the increased
11βHSD1 mRNA expression and enzyme activity seen in
SkM post dexamethasone treatment is associated with a
reduction in DNA methylation at the putative GRE of the
HSD11B1 P1 gene promoter in human diabetic subjects.
Results
The subjects consisted of seven males and eight females
with a median age 57 years (range 48 to 66 years). Over-
all they had moderately well controlled diabetes, with a
median (25th to 75th percentile) HbA1c of 6.9% (5.8 to
7.8%). All subjects had some degree of glucocorticoid-
induced hyperglycemia and insulin resistance following
dexamethasone treatment, with a significant increase in
fasting glucose, insulin and HOMA2-IR homeostasis
model assessment (Table 1).
Dexamethasone resulted in a significant increase in
11βHSD1 mRNA (P = 0.003), C/EBPβ mRNA (P = 0.015)
and increased 11βHSD1 oxoreductase activity (P = 0.017)
in SkM biopsies, as determined by the Wilcoxon signed-
rank test, which examines the significance of the median
difference between paired values (Table 1 and Figure 2). In
the 11 subjects where sufficient cDNA remained for the
determination of differential P1 and P2 promoter-
associated expression, there was a significant twofold in-
crease in the P1 promoter derived-transcript (P = 0.008)
and to a lesser extent the P2 promoter-derived transcript
(1.5-fold increase; P = 0.016).
DNA methylation β-values obtained for HSD11B1
promoters P1 (single CpG site) and P2 (3 CpG sites) are
listed in Table 2. In the case of P2, the averageTable 1 Patient characteristics before and after
dexamethasone 4 mg/day for 4 days
Characteristic Pre dexamethasone Post dexamethasone
Fasting glucose (mmol/l) 7.0 (6.1 to 9.8) 7.6 (6.4 to 12.9)a
Fasting insulin (mU/l) 13.1 (9.6 to 15.5) 15.8 (11.4 to 17.8)a
HOMA2-IR 2.0 (1.3 to 2.1) 2.4 (1.6 to 2.9)b
11βHSD1 mRNA (relative
expression)
3.06 (1.81 to 4.61) 3.06 (2.70 to 6.11)b
11βHSD1 oxoreductase
activity (% conversion)
11.3 (4.7 to 17.4) 15.5 (11.6 to 19.3)a
C/EBPβ mRNA (relative
expression)








0.83 (0.63 to 1.13) 1.40 (0.77 to 1.78)a
Data presented as median (25th to 75th percentile). The Wilcoxon signed-rank
test examined the significance of the median difference between paired
values. 11βHSD1, 11β-hydroxysteroid dehydrogenase-1; C/EBP, CCAAT/
enhancer-binding protein; HOMA, homeostasis model assessment. P <0.05
compared with pre dexamethasonea. P <0.01compared with
pre dexamethasoneb.
















Figure 2 Skeletal muscle 11β-hydroxysteroid dehydrogenase-1
mRNA, C/EBPβ and 11βHSD1 oxoreductase activity before and
after dexamethasone. Mean ± standard error of skeletal muscle (a)
11β-hydroxysteroid dehydrogenase-1(11βHSD1) mRNA, (b) CCAAT/
enhancer-binding protein (C/EBPβ) and (c) 11βHSD1 oxoreductase
activity before (□) and after (■ ) dexamethasone 4 mg/day for 4
days in 15 subjects with type 2 diabetes. *P <0.05, **P <0.01 by
Wilcoxon signed-rank test.methylation level was calculated from the three
analyzable CpG sites. The distal P1 region, containing a
putative GRE, showed a significant reduction in median
methylation level, from 32% to 30%, following dexa-
methasone treatment (P = 0.026). Furthermore, there
was a significant negative correlation via the Spearman
test between the change in methylation at this site and
Table 2 DNA methylation scores before and after








P1 promoter CpG 32 (29 to 35) 30 (28 to 33) 0.026
P2 promoter (CpG mean) 42 (37 to 43) 38 (36 to 41) 0.093
(P2_CpG 2) 22 (16 to 24) 18 (17 to 22) 0.072
(P2 _CpG 3) 41 (33 to 44) 37 (35 to 42) 0.409
(P2 _CpG 4) 63 (58 to 66) 59 (56 to 62) 0.065
Data presented as median (25th to 75th percentile). Methylation scores
(approximating % of alleles with cytosine methylation at specific CpG sites
within a tissue sample) were obtained from the Mass Spec output using
EpiTYPER v1.0.5 software (Sequenom Inc, San Diego, CA, USA). Only a single
CpG site was present in the P1 promoter region tested, whereas three sites in
close proximity were assessed in P2.
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(Figure 3, r = −0.62, P = 0.014). In the P2 promoter re-
gion, there was no significant change in total DNA
methylation across the three sites tested (P = 0.093), al-
though a consistent decrease in median methylation was
observed at each site post dexamethasone treatment.
There was not a significant correlation between the
change in 11βHSD1 mRNA and P1 methylation.
Discussion
We have previously demonstrated that oral dexametha-
sone administered at a dose of 4 mg/day for 4 days
increases 11βHSD1 oxoreductase activity in SkM of
subjects with type 2 diabetes but not nondiabetic
subjects [5]. We have now extended these findings by
examining the association of the DNA methylation level
in two annotated promoter regions with gene expression
levels and enzyme activity in the diabetic group, which is
subject to upregulation by dexamethasone. Evidence,





























Figure 3 Correlation between change in P1 promoter
methylation and 11β-hydroxysteroid dehydrogenase-1
oxoreductase activity in skeletal muscle. r = −0.62, P = 0.014.data, suggests that the HSD11B1 has two independent
transcription start sites and associated promoters,
designated P1 [14] and P2. In the mouse, the P1 pro-
moter predominates in the lung and is independent of
C/EBPα, while the P2 promoter predominates in the
liver, adipose tissue and brain [14]. At present the pre-
dominant transcriptional start site in SkM remains un-
clear, although our data confirm that both transcripts
are present. The P1 promoter region is CpG poor but
contains a conserved putative GRE upstream of the tran-
scriptional start site.
In this study we demonstrated that the dexamethasone-
induced increase in overall 11βHSD1 mRNA, derived
from both P1 and P2 promoters, and enzyme activity is
associated with a significantly reduced level of DNA
methylation at the putative GRE-associated CpG site
in HSD11B1 P1. Further, the extent of methylation re-
duction correlates significantly with the subsequent in-
crease in 11βHSD1 enzyme activity. While a statistical
association does not prove causality, the findings suggest
that HSD11B1 expression may be subject to dynamic
epigenetic modulation in response to glucocorticoid
status. This is further supported by the finding of sig-
nificant upregulation of the P1 promoter-derived tran-
script following dexamethasone treatment. The absolute
changes in methylation were small, but so were the
changes in SkM 11βHSD1 activity in many of the
subjects. Indeed in two subjects where a small decrease
in 11βHSD1 activity was observed, P1 promoter methy-
lation was increased or unchanged. Such a modest effect
size is in accordance with other emerging studies in
complex disease that routinely report small changes in
DNA methylation in a case–control setting. As an ex-
ample, Rakyan and colleagues identify small disease-
associated methylation differences of 1.3 to 6.6%, which
compare well with other multiple referenced studies in
complex disease and our data [20]. They point out that
this could be ‘the norm for complex disease associated
epigenetic variation’ [20].
While methylation of a single CpG site was analyzed
in the P1 promoter region, analysis of methylation of the
CpG sites within the P2 region did not produce
statistically significant changes following dexamethasone.
The dose of dexamethasone utilized in this study is
within the range used clinically, and completely
suppresses the hypothalamic–pituitary adrenal axis,
leading to the near absence of circulating cortisol. Dexa-
methasone induced insulin resistance in both diabetic
and nondiabetic subjects and resulted in an elevation in
fasting glucose, insulin and HOMA2-IR homeostasis
model assessment in the current study.
P2-associated transcription of HSD11B1 via the C/EBP
transcription factors has previously been described [11].
The 11βHSD1 P2 promoter contains 10 C/EBP binding
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regulation of 11βHSD1 appears to be tissue specific. In
HepG2 (hepatoma) cells, C/EBPα is the predominant
regulator of 11βHSD1 expression, while C/EBPβ is only
a weak activator in the absence of C/EBPα [15]. Both
C/EBPα and C/EBPβ are required for basal transcrip-
tional activity of 11βHSD1 in the mouse pre-adipocyte
cell line 3T3-L1 [12]. Induction of C/EBPα shows a
greater increase in basal 11βHSD1 expression, while
C/EBPβ is the key factor mediating the increase in
11βHSD1 in response to cyclic AMP stimulation in
these cells [12]. In human A549 lung epithelial cells,
the stimulatory effect of dexamethasone on 11βHSD1
activity appears to be mediated by two mechanisms.
Firstly, 11βHSD1 activity is dependent on the gluco-
corticoid receptor, since the co-administration of the
glucocorticoid receptor antagonist RU486 blocks it;
and secondly, the stimulatory effect of dexamethasone
is indirect requiring new protein synthesis, since the
glucocorticoid upregulation is also blocked by the protein
synthesis inhibitor cycloheximide [13]. While a GRE lies
between two key C/EBP binding sites in the P2 promoter,
mutation of this GRE region did not appear to affect
dexamethasone responsiveness [13]. C/EBPβ, but not
C/EBPα or C/EBPδ, is a crucial mediator of the increased
11βHSD1 expression and activity following dexametha-
sone in A549 cells [13]. In contrast, in the human adipo-
cyte cell line PAZ6, C/EBPα but not C/EBPβ or C/EBPδ
was induced by dexamethasone [21].
We have shown here that humans administered ex-
ogenous dexamethasone exhibit a significant rise in SkM
C/EBPβ mRNA levels consistent with the findings of
Yang and colleagues [16]. The extent of the increase in
C/EBPβ and 11βHSD1 in SkM was considerably less
than observed by Sai and colleagues, who showed a
12-fold increase in 11βHSD1 mRNA levels in response
to a threefold to fourfold increase in C/EBPβ in A549
lung epithelial cells [13]. Since our data demonstrated an
increase in expression of both P1 and P2 promoters, we
suggest that there may be a dual mechanism of
dexamethasone-induced activation of SkM 11βHSD1 ac-
tivity; via demethylation of the P1 promoter and through
C/EBPβ stimulation of the P2 promoter.
In SkM, the precise mechanism(s) involved in
glucocorticoid-induced activation of 11βHSD remain to
be characterized. Which promoter (P1 or P2) is used in
muscle to transcribe the HSD11B1 gene in response to
glucocorticoid was previously not known, although we
have now shown that both transcripts are clearly detect-
able by specific RT-PCR. In vitro reporter experiments
aimed at demonstrating functionality of the putative
P1-associated GRE in appropriate cell models are
required to confirm the functionality of this region in the
observed glucocorticoid response. The P2-associatedCpG sites are not associated with a putative GRE,
suggesting that a reduction in methylation at the P2
promoter of HSD11B1 is not associated with the
increased SkM 11βHSD1 activity following dexametha-
sone administration.
The enzyme 11βHSD type 2 (11βHSD2), which
converts cortisol to cortisone, is highly expressed in
mineralocorticoid target tissues such as the kidney and
colon, but is expressed at low levels in SkM [5]. There
is evidence that 11βHSD2 is subject to epigenetic
regulation, both at the level of DNA methylation but
also of the histone modification profile [22]. Human
subjects who developed hypertension when treated
with prednisone had increased 11βHSD2 promoter
methylation in peripheral blood mononuclear cells
[23]. Our previous work demonstrated that SkM
11βHSD2 expression and activity was downregulated
in the type 2 diabetic subjects [5]. This downregulation
may thus possibly be associated with increased methy-
lation of the 11βHSD2 promoter, but this was not the
focus of the present study.
Methylation of DNA is a well-described mechanism of
epigenetic modulation of gene expression. DNA methyla-
tion had been assumed not to be as dynamic as other
epigenetic processes. However, recent studies have
demonstrated that highly dynamic DNA methylation
changes can occur even during the relatively short period
of a single cell cycle in a number of human genes [13,19].
Other studies have examined epigenetic mechanisms
in metabolic pathways in SkM of human subjects. Non-
CpG methylation of the peroxisome proliferator-
activated receptor γ coactivator-1α (PGC-1α) gene
in myotubes has been associated with reductions
in mitochondrial density in subjects with type 2 diabetes
[24]. Furthermore, elevated DNA methylation of SkM
PGC-1α is observed in normal birth weight nondiabetic
subjects overfed a high-fat diet [25]. Our findings sup-
port the involvement of DNA methylation at the
conserved putative GRE in the P1 11βHSD1 promoter
in the regulation of glucocorticoid-induced HSD11B1
gene activation in human SkM. Specifically, we find
that the extent of the reduction in methylation of this
GRE following dexamethasone correlates with the
subsequent increment in SkM 11βHSD1 oxoreductase
activity. While the putative GRE in the P1 11βHSD1
promoter may have a lesser role compared with C/EBP-
stimulated P2 promoter activation in many tissues,
our results suggest that even relatively small changes
in methylation may influence the extent of the incre-
ment in SkM 11βHSD1 activity. However, this does not
preclude the existence of a parallel response involving
C/EBPβ action at the P2 promoter. Further functional
studies are required to determine the relative contribu-
tion of these promoter regions and regulatory
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gene in SkM.
Conclusion
This study has found a reduction in methylation of the
putative GRE within the P1 promoter of HSD11B1 that
correlates with gene expression and the increase in
11βHSD1 oxoreductase activity in SkM following dexa-
methasone treatment. This observation implicates dy-
namic epigenetic remodeling in the regulation of
glucocorticoid action via 11βHSD1.
Methods
The experimental protocol was approved by the institu-
tional Human Research Ethics Committee. Fifteen
volunteers with type 2 diabetes gave written informed con-
sent for participation. The subjects were treated by diet
alone (n = 4) or with oral hypoglycemic agents (metformin
alone, n = 2; a sulphonylurea alone, n = 2; or both, n = 7).
No patient was using insulin or thiazolidinediones. Ex-
clusion criteria included poorly controlled hypertension
(systolic blood pressure ≥160 mmHg and/or diastolic
blood pressure ≥90 mmHg), a history of liver or renal
disease, and evidence of unstable angina or peripheral
vascular disease. Data from 12 of these subjects were
included in our previous study examining the effect of
oral dexamethasone on 11βHSD1 and 11βHSD2 in dia-
betic and nondiabetic subjects [5]. Nondiabetic subjects
were not included in this study because we had previously
shown that the induction of 11βHSD1 oxoreductase activ-
ity did not occur in this group.
Experimental design
After an overnight 10-hour fast, subjects had venous
blood samples drawn between 08:00 and 08:30 hours for
glucose, insulin and HbA1c. Body weight, body mass
index and waist-to-hip ratio were determined for each
subject.
After sedation with intravenous midazolam and ad-
ministration of local anesthetic, biopsy of the vastus
lateralis was performed using a 5 mm Bergstrom needle
as previously described [26]. Fresh muscle was rapidly
dissected of visible adipose and connective tissue and
placed in DMEM for enzyme activity studies. Additional
SkM from the same biopsy was snap-frozen in liquid ni-
trogen for mRNA analysis and epigenetic studies, with
storage at −70C. Within 28 days, subjects were
administered oral dexamethasone (4 mg daily) for 4 days
before repeat blood sampling and muscle biopsy. The
subjects were clear that the dexamethasone was being
administered for experimental rather than therapeutic
purposes, and warned that dexamethasone would in-
crease their blood glucose levels. They monitored their
capillary blood glucose levels at least twice daily duringdexamethasone therapy, and were contacted by an inves-
tigator on a daily basis.
Laboratory assays
Plasma glucose was analyzed by a glucose oxidase
method employing a YSI 1500 Sidekick analyzer (Yellow
Springs Instrument Company, Yellow Springs, OH,
USA), with coefficient of variation 2.4%. Plasma insulin
was measured with a radioimmunoassay, with <1%
cross-reactivity to proinsulin and sensitivity of 0.5 mU/l.
Insulin antibodies were not present in any sample.
HbA1c was measured by a high-performance liquid
chromatography assay. Homeostasis model assessment
was calculated using the computer program of Levy and
colleagues [27].
Quantitative real-time RT-PCR
Relative SkM mRNA levels for 11βHSD1 and C/EBPβ
were determined using quantitative real-time RT-PCR
(TaqmanW, Applied Biosystems, Foster City, CA, USA ).
Singleplex reactions were performed using 11βHSD1
specific primers with normalization to the endogenous
control human 18s rRNA (Applied Biosystems, Foster
City, CA, USA) as in our previous studies [5,26]. The
RT-PCR product overlapped exons 2 and 3 of the
HSD11B1 gene. Relative 11βHSD1 mRNA levels were
calculated using the ΔΔCT methodology (using the for-
mula 2ΔΔCT). Human C/EBPβ expression levels were
assessed using a specific pre-validated assay obtained
from Applied Biosystems. Total RNA from commercially
obtained human SkM (BD Biosciences, Palo Alto, CA,
USA) was reverse transcribed to cDNA and was used as
the calibrator in all experiments. The ΔCT value for each
subject was expressed as a ratio with the ΔCT measured
from the commercially obtained SkM cDNA. Sufficient
cDNA allowed quantification of the P1 and P2 promoter
regions of HSD11B1 before and after dexamethasone in
11/15 subjects.
11β-Hydroxysteroid dehydrogenase-1 enzyme activity
Oxoreductase enzyme activity of 11βHSD1 was determined
in dispersed fresh SkM after overnight incubation, by meas-
uring the conversion of radiolabeled 3H-cortisone to corti-
sol by thin layer chromatography, as described in our
previous studies [5,26].
Genomic DNA extraction
Muscle samples were incubated at 50C overnight in DNA
extraction buffer (100 mM NaCl, 10 mM Tris–HCl pH 8,
25 mM ethylenediamine tetraacetic acid, 0.5% SDS) with
200 μg/ml Proteinase K. DNA was then isolated by two
rounds of phenol–chloroform extraction, followed by
RNAse A treatment, precipitation in ethanol containing
10% sodium acetate (3 M, pH 5.2), with resuspension in
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USA). DNA was quantitated and quality assessed by spec-
trophotometry on a Nanodrop (ThermoFisher Scientific,
Waltham, MA, USA), and checked for integrity by gel elec-
trophoresis, with subsequent storage at −20C.
HSD11B1 promoter methylation
Figure 1 outlines the location of the HSD11B1 promoter
methylation assays used in this study. Sequenom
MassARRAY EpiTYPING was carried out as previously
described [28,29]. DNA samples were processed using
the Methyl Easy bisulphite modification kit (Human
Genetic Signatures, North Ryde, NSW, Australia)
according to the manufacturer’s instructions. Amplifica-
tion was performed on converted genomic DNA using
primers directed to modified DNA: 11HSDB1_F1, 50-
aggaagagagTGGTGAAAAGGGAAAATTTGTTT and
11HSDB1_R1, 50-cagtaatacgactcactatagggagaaggctCCT
ACAAAAACAACTCCAAAAAA for distal promoter
1 (P1); and 11HSDB1_F2, 50-aggaagagagTTTTTGAA
AGATTATTGATTTTTGG and 11HSDB1_R2, 50-cagt
aatacgactcactatagggagaaggctTCCTATAAAACACACAAAA
AAAACC for proximal promoter 2 (P2) (lowercase denotes
sequence tags added to facilitate downstream EpiTYPER
analysis). EpiTYPER analysis produces a methylation
β-value (approximately equivalent to total percentage
methylation). All PCR amplifications and subsequent
MassArray runs were performed in triplicate for calcu-
lation of mean methylation β-values at each analyzable
CpG site.
Statistical analysis
The raw data failed to satisfy parametric assumptions,
and therefore nonparametric tests were used in the ana-
lysis. Tabulated data are expressed as the median (25th
to 75th percentile), while Figure 2 presents the mean ±
standard error of the mean. The mRNA expression,
11βHSD1 enzyme activity and changes in promoter
DNA methylation score in response to dexamethasone
were analyzed by the Wilcoxon signed-rank test, which
examines the significance of the median difference be-
tween paired values. The correlation between the in-
cremental response of 11βHSD1 activity and changes
in mean promoter methylation was analyzed by the
Spearman correlation coefficient. The level of statistical
significance was set at P <0.05.
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